8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Mar 27, 2026·SEC
Ocugen, Inc.(OCGN)Earnings, Financials & Key Ratios
OCGN•NASDAQ
$1.46
$493M mkt cap·Price updated May 6, 2026
AboutOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.Show more
- Revenue$4M+8.8%
- EBITDA-$61M-14.7%
- Net Income-$68M-25.5%
- EPS (Diluted)-0.23-15.0%
- Gross Margin45.86%-10.9%
- EBITDA Margin-1371.56%-5.4%
- Operating Margin-1425.7%-5.6%
- Net Margin-1537.41%-15.3%
- ROE-776.89%-404.4%
- ROIC-1565.59%-122.3%
- Interest Coverage-12.13
OCGN Key Insights
Ocugen, Inc. (OCGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 152.5%
✗Weaknesses
- ✗Profits declining 25.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 10.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OCGN Price & Volume
Ocugen, Inc. (OCGN) stock price & volume — 10-year historical chart
Loading chart...
OCGN Growth Metrics
Ocugen, Inc. (OCGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years152.5%
3 Years21.05%
TTM8.83%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-25.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-24.96%
Return on Capital
10 Years-128.28%
5 Years-110.58%
3 Years-119.53%
Last Year-154.72%
OCGN Recent Earnings
Ocugen, Inc. (OCGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (83%)
Q2 2026Latest
May 5, 2026EPS
$0.06
Est $0.05
-20.0%
Revenue
$2M
Est $417,833
+266.9%
Q2 2026
Mar 4, 2026EPS
$0.06
Est $0.06
+0.0%
Revenue
$193,000
Est $1M
-118.0%
Q4 2025
Nov 5, 2025EPS
$0.07
Est $0.06
-21.7%
Revenue
$2M
Est $440,000
+298.2%
Q3 2025
Aug 1, 2025EPS
$0.05
Est $0.06
+16.7%
Revenue
$1M
Est $300,000
+357.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.06vs $0.05-20.0% | $2Mvs $417,833+266.9% |
| Q2 2026 | Mar 4, 2026 | $0.06vs $0.06+0.0% | $193,000vs $1M-118.0% |
| Q4 2025 | Nov 5, 2025 | $0.07vs $0.06-21.7% | $2Mvs $440,000+298.2% |
| Q3 2025 | Aug 1, 2025 | $0.05vs $0.06+16.7% | $1Mvs $300,000+357.7% |
Based on last 12 quarters of dataView full earnings history →
OCGN Peer Comparison
Ocugen, Inc. (OCGN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REPL | 272.34M | 3.42 | -1.11 | -149.55% | 0.18 | |||
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 | ||
 BOLD | 35.4M | 1.58 | -0.61 | -49.73% | 0.50 |
Compare OCGN vs Peers
Ocugen, Inc. (OCGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCGN Income Statement
Ocugen, Inc. (OCGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 43K | 0 | 2.49M | 6.04M | 4.05M | 4.41M |
| Revenue Growth % | - | - | - | - | -100% | - | 142.6% | -32.82% | 8.83% |
| Cost of Goods Sold | 1.53M | 49.62K | 8.09M | 6.35M | 0 | 0 | 704K | 1.97M | 2.39M |
| COGS % of Revenue | - | - | - | 14776.74% | - | - | 11.66% | 48.53% | 54.14% |
| Gross Profit | -1.53M▲ 0% | -49.62K▲ 96.8% | -8.09M▼ 16194.9% | -6.31M▲ 22.0% | 0▲ 100.0% | 2.49M▲ 0% | 5.33M▲ 114.3% | 2.09M▼ 60.9% | 2.02M▼ 3.0% |
| Gross Margin % | - | - | - | -14676.74% | - | 100% | 88.34% | 51.47% | 45.86% |
| Gross Profit Growth % | 8.31% | 96.77% | -16194.86% | 21.95% | 100% | - | 114.31% | -60.86% | -3.02% |
| Operating Expenses | 24.95M | 25.84M | 6.08M | 14.97M | 58.03M | 91.56M | 70.86M | 56.84M | 64.94M |
| OpEx % of Revenue | - | - | - | 34823.26% | - | 3680.02% | 1174.01% | 1401.82% | 1471.56% |
| Selling, General & Admin | 9.38M | 10.2M | 6.08M | 7.97M | 22.92M | 35.4M | 31.99M | 26.69M | 27.58M |
| SG&A % of Revenue | - | - | - | 18544.19% | - | 1422.83% | 530.05% | 658.1% | 624.95% |
| Research & Development | 15.57M | 15.63M | 8.09M | 13.35M | 35.11M | 56.16M | 39.57M | 32.13M | 39.75M |
| R&D % of Revenue | - | - | - | 31055.81% | - | 2257.19% | 655.62% | 792.26% | 900.75% |
| Other Operating Expenses | -116K | 0 | -8.09M | -6.35M | 0 | 0 | -704K | -1.97M | -2.39M |
| Operating Income | -24.95M▲ 0% | -30.11M▼ 20.7% | -14.16M▲ 53.0% | -21.29M▼ 50.3% | -58.03M▼ 172.6% | -89.07M▼ 53.5% | -65.53M▲ 26.4% | -54.76M▲ 16.4% | -62.92M▼ 14.9% |
| Operating Margin % | - | - | - | -49500% | - | -3580.02% | -1085.67% | -1350.36% | -1425.7% |
| Operating Income Growth % | 17.68% | -20.67% | 52.96% | -50.29% | -172.62% | -53.5% | 26.43% | 16.44% | -14.9% |
| EBITDA | -23.42M | -30.06M | -14.1M | -21.18M | -57.8M | -88.59M | -64.83M | -52.79M | -60.53M |
| EBITDA Margin % | - | - | - | -49262.79% | - | -3560.73% | -1074.01% | -1301.82% | -1371.56% |
| EBITDA Growth % | 18.22% | -28.37% | 53.08% | -50.21% | -172.86% | -53.27% | 26.82% | 18.57% | -14.66% |
| D&A (Non-Cash Add-back) | 1.53M | 49.62K | 61K | 102K | 229K | 480K | 704K | 1.97M | 2.39M |
| EBIT | -26.41M | -14.47M | -14.16M | -14.29M | -58.03M | -89.07M | -65.53M | -54.76M | -62.92M |
| Net Interest Income | 0 | 0 | -1.77M | -719.9K | -79K | 1.4M | 2.5M | 1.3M | -4.27M |
| Interest Income | 0 | 0 | 1.21K | 1.06K | 0 | 1.4M | 2.5M | 1.3M | 922K |
| Interest Expense | 134K | 163K | 1.77M | 720.96K | 79K | 0 | 0 | 0 | 5.19M |
| Other Income/Expense | -1.46M | 11.89M | -6.08M | -537K | -389K | 2.27M | 2.45M | 703K | -4.93M |
| Pretax Income | -26.41M▲ 0% | -8.64M▲ 67.3% | -20.24M▼ 134.2% | -21.82M▼ 7.8% | -58.42M▼ 167.7% | -86.8M▼ 48.6% | -63.08M▲ 27.3% | -54.05M▲ 14.3% | -67.85M▼ 25.5% |
| Pretax Margin % | - | - | - | -50748.84% | - | -3488.91% | -1045.03% | -1333.02% | -1537.41% |
| Income Tax | -186K | -15.76M | 0 | 0 | -52K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.7% | 182.36% | 0% | 0% | 0.09% | 0% | 0% | 0% | 0% |
| Net Income | -26.41M▲ 0% | -8.64M▲ 67.3% | -20.24M▼ 134.2% | -21.82M▼ 7.8% | -58.37M▼ 167.5% | -86.8M▼ 48.7% | -63.08M▲ 27.3% | -54.05M▲ 14.3% | -67.85M▼ 25.5% |
| Net Margin % | - | - | - | -50748.84% | - | -3488.91% | -1045.03% | -1333.02% | -1537.41% |
| Net Income Growth % | -62.97% | 67.28% | -134.21% | -7.8% | -167.46% | -48.73% | 27.33% | 14.31% | -25.52% |
| Net Income (Continuing) | -26.41M | -18.22M | -20.24M | -21.82M | -58.37M | -86.8M | -63.08M | -54.05M | -67.85M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -69.91▲ 0% | -13.98▲ 80.0% | -1.53▲ 89.1% | -0.31▲ 79.7% | -0.30▲ 3.2% | -0.40▼ 33.3% | -0.26▲ 35.0% | -0.20▲ 23.1% | -0.23▼ 15.0% |
| EPS Growth % | -3.45% | 80% | 89.06% | 79.74% | 3.23% | -33.33% | 35% | 23.08% | -15% |
| EPS (Basic) | -69.91 | -13.98 | -1.53 | -0.31 | -0.30 | -0.40 | -0.26 | -0.20 | -0.23 |
| Diluted Shares Outstanding | 377.84K | 618.18K | 13.89M | 112.24M | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
| Basic Shares Outstanding | 377.83K | 618.18K | 13.89M | 112.24M | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
OCGN Balance Sheet
Ocugen, Inc. (OCGN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.18M | 16.4M | 15.77M | 25.88M | 102.65M | 98.49M | 42.97M | 61.68M | 24.34M |
| Cash & Short-Term Investments | 7.98M | 15.54M | 7.44M | 24.04M | 94.96M | 90.93M | 39.46M | 58.51M | 18.57M |
| Cash Only | 7.08M | 15.54M | 7.44M | 24.04M | 94.96M | 77.56M | 39.46M | 58.51M | 18.57M |
| Short-Term Investments | 900K | 0 | 0 | 0 | 0 | 13.37M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 122K | 172K | 7M | 0 | 0 | 7.56M | 3.51M | 3.17M | 5.77M |
| Total Non-Current Assets | 2.86M | 1.03M | 1.04M | 1.5M | 3.12M | 10.14M | 21.58M | 20.76M | 19.18M |
| Property, Plant & Equipment | 2.72M | 141K | 222.46K | 633K | 1.16M | 6.05M | 17.29M | 16.55M | 14.39M |
| Fixed Asset Turnover | - | - | - | 0.07x | - | 0.41x | 0.35x | 0.24x | 0.31x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 137K | 150.48K | 151.02K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 736.52K | 667.75K | 865K | 1.95M | 4.09M | 4.29M | 4.21M | 4.78M |
| Total Assets | 11.04M▲ 0% | 17.43M▲ 57.9% | 16.81M▼ 3.6% | 27.38M▲ 62.9% | 105.76M▲ 286.3% | 108.63M▲ 2.7% | 64.55M▼ 40.6% | 82.44M▲ 27.7% | 43.52M▼ 47.2% |
| Asset Turnover | - | - | - | 0.00x | - | 0.02x | 0.09x | 0.05x | 0.10x |
| Asset Growth % | -69.41% | 57.93% | -3.56% | 62.88% | 286.33% | 2.71% | -40.58% | 27.72% | -47.22% |
| Total Current Liabilities | 3.81M | 2.87M | 4.54M | 3.61M | 7M | 28.53M | 17.09M | 21.59M | 23.04M |
| Accounts Payable | 776K | 1.59M | 1.9M | 395K | 2.31M | 8.06M | 3.17M | 4.24M | 6.2M |
| Days Payables Outstanding | 184.64 | 11.7K | 85.57 | 22.69 | - | - | 1.64K | 786.94 | 947.56 |
| Short-Term Debt | 178K | 0 | 0 | 234K | 0 | 0 | 0 | 1.33M | 1.25M |
| Deferred Revenue (Current) | 2.02M | 10M | 2.27M | 0 | 0 | 11.22M | 10.53M | 8.37M | 5.91M |
| Other Current Liabilities | 1.18M | 948K | -2.06M | 1.68M | 1.72M | 3.11M | 1.03M | 5.25M | 6.69M |
| Current Ratio | 2.15x | 5.71x | 3.47x | 7.16x | 14.66x | 3.45x | 2.51x | 2.86x | 1.06x |
| Quick Ratio | 2.15x | 5.71x | 3.47x | 7.16x | 14.66x | 3.45x | 2.51x | 2.86x | 1.06x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 18.5M | 15.01M | 1.25M | 2.21M | 2.94M | 6.12M | 6.89M | 31.22M | 32.64M |
| Long-Term Debt | 0 | 1.02M | 1.07M | 1.82M | 1.71M | 2.29M | 2.8M | 27.34M | 27.54M |
| Capital Lease Obligations | 0 | 0 | 163.2K | 389K | 1.23M | 3.59M | 3.57M | 3.31M | 3.49M |
| Deferred Tax Liabilities | 0 | -1.02M | 0 | 0 | 0 | 0 | 918K | 0 | 0 |
| Other Non-Current Liabilities | 18.5M | 4M | 9.76K | 0 | 0 | 244K | 527K | 564K | 1.6M |
| Total Liabilities | 22.3M | 17.89M | 5.79M | 5.83M | 9.94M | 34.65M | 23.98M | 52.81M | 55.68M |
| Total Debt | 178K | 238K | 1.41M | 2.49M | 3.31M | 6.37M | 6.94M | 32.5M | 33.14M |
| Net Debt | -6.9M | -15.3M | -6.04M | -21.55M | -91.65M | -71.19M | -32.52M | -26.01M | 14.57M |
| Debt / Equity | - | - | 0.13x | 0.12x | 0.03x | 0.09x | 0.17x | 1.10x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -197.12x | -88.77x | -8.01x | -19.81x | -734.53x | - | - | - | -12.13x |
| Total Equity | -11.27M▲ 0% | -458K▲ 95.9% | 11.02M▲ 2505.8% | 21.55M▲ 95.6% | 95.82M▲ 344.6% | 73.98M▼ 22.8% | 40.56M▼ 45.2% | 29.63M▼ 27.0% | -12.17M▼ 141.1% |
| Equity Growth % | -183.05% | 95.94% | 2505.77% | 95.58% | 344.63% | -22.79% | -45.17% | -26.95% | -141.06% |
| Book Value per Share | -29.82 | -0.74 | 0.79 | 0.19 | 0.49 | 0.34 | 0.17 | 0.11 | -0.04 |
| Total Shareholders' Equity | -11.27M | -458K | 11.02M | 21.55M | 95.82M | 73.98M | 40.56M | 29.63M | -12.17M |
| Common Stock | 159K | 513K | 527.47K | 1.84M | 2M | 2.22M | 2.57M | 2.92M | 3.13M |
| Retained Earnings | -208.19M | -216.83M | -51.48M | -73.3M | -131.67M | -223.09M | -286.17M | -340.22M | -408.07M |
| Treasury Stock | 0 | 0 | -47.86K | -48K | -48K | -48K | -48K | -48K | -48K |
| Accumulated OCI | -10.92M | -10.29M | 0 | 0 | 0 | 26K | 20K | 48K | 61K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCGN Cash Flow Statement
Ocugen, Inc. (OCGN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -23.02M | -15.78M | -16.89M | -14.71M | -47.94M | -60.08M | -62.05M | -42.14M | -56.96M |
| Operating CF Margin % | - | - | - | -34206.35% | - | -2414.75% | -1028.06% | -1039.26% | -1290.82% |
| Operating CF Growth % | 10.55% | 31.46% | -7.08% | 12.93% | -225.94% | -25.32% | -3.29% | 32.09% | -35.17% |
| Net Income | -26.41M | -8.64M | -20.24M | -21.82M | -58.37M | -86.8M | -63.08M | -54.05M | -67.85M |
| Depreciation & Amortization | 1.53M | 450K | 60.61K | 102.11K | 229K | 480K | 704K | 1.97M | 2.39M |
| Stock-Based Compensation | 1.57M | 1.63M | 884.09K | 660K | 6.96M | 10.54M | 9.22M | 7.43M | 7.71M |
| Deferred Taxes | 1.54M | -17.14M | 3.19M | 0 | -52K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -543K | 10.73M | 2.33M | 7.56M | 799K | 6.51M | 4.26M | -1.15M | 1.31M |
| Working Capital Changes | -706K | -2.81M | -3.11M | -1.21M | 2.49M | 9.2M | -13.16M | 3.67M | -523K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.21M | -375K | -1.63B | -540.85M | 3.5M | 0 | 0 | 0 | 0 |
| Cash from Investing | -1.23M | -1.11M | -2.36M | -306.82K | -1.82M | -16.97M | 3.08M | -3.38M | -311K |
| Capital Expenditures | -276K | -2.01M | -29.45K | -306.82K | -939K | -4.46M | -10.48M | -3.38M | -185K |
| CapEx % of Revenue | - | - | - | 713.55% | - | 179.14% | 173.56% | 83.48% | 4.19% |
| Acquisitions | 0 | 0 | -2.33M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -273 | 0 | -877K | 761K | 0 | 0 | -126K |
| Cash from Financing | -577K | 25.35M | 25.07M | 31.61M | 120.68M | 59.48M | 20.88M | 64.86M | 17.33M |
| Debt Issued (Net) | -583K | -178K | 1.38M | -4.73M | -10K | 500K | 500K | 30M | -1M |
| Equity Issued (Net) | 0 | 25.53M | 23.68M | 37.82M | 129.21M | 59.57M | 20.45M | 38.56M | 18.33M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -48K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 6K | 3K | 0 | -1.48M | -8.53M | -592K | -68K | -3.7M | 0 |
| Net Change in Cash | -24.83M▲ 0% | 8.46M▲ 134.1% | 5.82M▼ 31.3% | 16.6M▲ 185.3% | 70.92M▲ 327.3% | -17.55M▼ 124.7% | -38.1M▼ 117.1% | 19.36M▲ 150.8% | -39.93M▼ 306.3% |
| Free Cash Flow | -23.3M▲ 0% | -17.79M▲ 23.6% | -16.92M▲ 4.9% | -15.02M▲ 11.3% | -48.88M▼ 225.5% | -64.54M▼ 32.0% | -72.53M▼ 12.4% | -45.53M▲ 37.2% | -57.15M▼ 25.5% |
| FCF Margin % | - | - | - | -34919.9% | - | -2593.89% | -1201.62% | -1122.74% | -1295.01% |
| FCF Growth % | 10.59% | 23.64% | 4.88% | 11.27% | -225.53% | -32.03% | -12.39% | 37.23% | -25.53% |
| FCF per Share | -61.66 | -28.78 | -1.22 | -0.13 | -0.25 | -0.30 | -0.30 | -0.17 | -0.19 |
| FCF Conversion (FCF/Net Income) | 0.87x | 1.83x | 0.83x | 0.67x | 0.82x | 0.69x | 0.98x | 0.78x | 0.84x |
| Interest Paid | 30K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 197K | 105K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCGN Key Ratios
Ocugen, Inc. (OCGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -77.62% | -2297.87% | - | -383.38% | -134.01% | -99.46% | -102.24% | -110.14% | -154.01% | -776.89% |
| Return on Invested Capital (ROIC) | - | - | - | - | -640.73% | -2088.84% | -1920.19% | -907.21% | -704.18% | -1565.59% |
| Gross Margin | - | - | - | - | -14676.74% | - | 100% | 88.34% | 51.47% | 45.86% |
| Net Margin | - | - | - | - | -50748.84% | - | -3488.91% | -1045.03% | -1333.02% | -1537.41% |
| Debt / Equity | 0.06x | - | - | 0.13x | 0.12x | 0.03x | 0.09x | 0.17x | 1.10x | - |
| Interest Coverage | -217.47x | -197.12x | -88.77x | -8.01x | -19.81x | -734.53x | - | - | - | -12.13x |
| FCF Conversion | 1.59x | 0.87x | 1.83x | 0.83x | 0.67x | 0.82x | 0.69x | 0.98x | 0.78x | 0.84x |
| Revenue Growth | - | - | - | - | - | -100% | - | 142.6% | -32.82% | 8.83% |
OCGN SEC Filings & Documents
Ocugen, Inc. (OCGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
OCGN Frequently Asked Questions
Ocugen, Inc. (OCGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ocugen, Inc. (OCGN) reported $4.4M in revenue for fiscal year 2025. This represents a 16873% increase from $0.0M in 2012.
Ocugen, Inc. (OCGN) grew revenue by 8.8% over the past year. This is steady growth.
Ocugen, Inc. (OCGN) reported a net loss of $67.8M for fiscal year 2025.
Dividend & Returns
Ocugen, Inc. (OCGN) has a return on equity (ROE) of -776.9%. Negative ROE indicates the company is unprofitable.
Ocugen, Inc. (OCGN) had negative free cash flow of $57.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More OCGN
Ocugen, Inc. (OCGN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates